New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - entecavir monohydrate 0.53mg equivalent to 0.5 mg entecavir (anhydrous) - film coated tablet - 0.5 mg - active: entecavir monohydrate 0.53mg equivalent to 0.5 mg entecavir (anhydrous) excipient: crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1r-7003 purified water - entecavir is indicated for the treatment of chronic hbv infection in adults with evidence of active liver inflammation.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - entecavir monohydrate 1.06mg equivalent to 1 mg entecavir (anhydrous) - film coated tablet - 1 mg - active: entecavir monohydrate 1.06mg equivalent to 1 mg entecavir (anhydrous) excipient: crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1r-7003 purified water - entecavir is indicated for the treatment of chronic hbv infection in adults with evidence of active liver inflammation.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - efavirenz 600mg;  ; emtricitabine 200mg;  ; tenofovir disoproxil maleate 300mg equivalent to 245 mg tenofovir disoproxil - film coated tablet - active: efavirenz 600mg   emtricitabine 200mg   tenofovir disoproxil maleate 300mg equivalent to 245 mg tenofovir disoproxil excipient: colloidal silicon dioxide croscarmellose sodium hyprolose low-substituted hydroxypropylcellulose, lh 11 iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink 85f540043 sodium metabisulfite - indicated for the treatment of hiv infected adults over the age of 18 years, alone or in combination with other antiretroviral agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - rosuvastatin calcium 10.396mg equivalent to rosuvastatin 10 mg - film coated tablet - 10 mg - active: rosuvastatin calcium 10.396mg equivalent to rosuvastatin 10 mg excipient: colloidal silicon dioxide crospovidone iron oxide red lactose monohydrate light magnesium oxide magnesium stearate microcrystalline cellulose opadry pink - rosuvastatin calcium is indicated to: · reduce elevated ldl-c, total cholesterol, triglycerides and to increase hdlcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (fredrickson types iia and iib). rosuvastatin calcium also lowers apob, nonhdl-c, vldl-c, vldl-tg, the ldl-c/hdl-c, total c/hdl-c, nonhdl-c/hdl-c, apob/apoa-i ratios and increase apo-a-i in these populations. · treat isolated hypertriglyceridaemia (fredrickson type iv hyperlipidaemia). · reduce total cholesterol and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or alone if such treatments are unavailable.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - rosuvastatin calcium 20.792mg equivalent to rosuvastatin 20 mg - film coated tablet - 20 mg - active: rosuvastatin calcium 20.792mg equivalent to rosuvastatin 20 mg excipient: colloidal silicon dioxide crospovidone iron oxide red lactose monohydrate light magnesium oxide magnesium stearate microcrystalline cellulose opadry pink - rosuvastatin calcium is indicated to: · reduce elevated ldl-c, total cholesterol, triglycerides and to increase hdlcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (fredrickson types iia and iib). rosuvastatin calcium also lowers apob, nonhdl-c, vldl-c, vldl-tg, the ldl-c/hdl-c, total c/hdl-c, nonhdl-c/hdl-c, apob/apoa-i ratios and increase apo-a-i in these populations. · treat isolated hypertriglyceridaemia (fredrickson type iv hyperlipidaemia). · reduce total cholesterol and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or alone if such treatments are unavailable.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - rosuvastatin calcium 41.584mg equivalent to rosuvastatin 40 mg - film coated tablet - 40 mg - active: rosuvastatin calcium 41.584mg equivalent to rosuvastatin 40 mg excipient: colloidal silicon dioxide crospovidone iron oxide red lactose monohydrate light magnesium oxide magnesium stearate microcrystalline cellulose opadry pink - rosuvastatin calcium is indicated to: · reduce elevated ldl-c, total cholesterol, triglycerides and to increase hdlcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (fredrickson types iia and iib). rosuvastatin calcium also lowers apob, nonhdl-c, vldl-c, vldl-tg, the ldl-c/hdl-c, total c/hdl-c, nonhdl-c/hdl-c, apob/apoa-i ratios and increase apo-a-i in these populations. · treat isolated hypertriglyceridaemia (fredrickson type iv hyperlipidaemia). · reduce total cholesterol and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or alone if such treatments are unavailable.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - rosuvastatin calcium 5.198mg equivalent to rosuvastatin 5 mg - film coated tablet - 5 mg - active: rosuvastatin calcium 5.198mg equivalent to rosuvastatin 5 mg excipient: colloidal silicon dioxide crospovidone iron oxide red lactose monohydrate light magnesium oxide magnesium stearate microcrystalline cellulose opadry yellow - rosuvastatin calcium is indicated to: · reduce elevated ldl-c, total cholesterol, triglycerides and to increase hdlcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (fredrickson types iia and iib). rosuvastatin calcium also lowers apob, nonhdl-c, vldl-c, vldl-tg, the ldl-c/hdl-c, total c/hdl-c, nonhdl-c/hdl-c, apob/apoa-i ratios and increase apo-a-i in these populations. · treat isolated hypertriglyceridaemia (fredrickson type iv hyperlipidaemia). · reduce total cholesterol and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or alone if such treatments are unavailable.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - abacavir sulfate 702.78mg equivalent to abacavir 600 mg;  ; lamivudine 300mg - film coated tablet - active: abacavir sulfate 702.78mg equivalent to abacavir 600 mg   lamivudine 300mg excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry white 13b58894 purified talc silicified microcrystalline cellulose - antiretroviral combination therapy for the treatment of hiv in adults and adolescents from 12 years of age.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ambrisentan 10mg - film coated tablet - 10 mg - active: ambrisentan 10mg excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry pink 85f540046 purified water - indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary arterial hypertension associated with connective tissue disease (pah-ctd), in patients with who functional class ii, iii or iv symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ambrisentan 5mg - film coated tablet - 5 mg - active: ambrisentan 5mg excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry pink 85f540046 purified water - indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary arterial hypertension associated with connective tissue disease (pah-ctd), in patients with who functional class ii, iii or iv symptoms.